{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:06:01Z","timestamp":1790687161103,"version":"4.1.0"},"reference-count":107,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The development of inhibitors with factor VIII (FVIII) replacement therapy is one of the most common and challenging complications of haemophilia A (HA) treatment, jeopardising treatment efficacy and predisposing patients to high risks of morbidity and mortality. The management of patients with inhibitors is particularly challenging in countries where resources are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To provide a comprehensive summary of the management of HA with inhibitors while focusing on differences in practice between Western and non\u2010Western countries and how resource scarcity can impact HA management, leading to suboptimal outcomes in patients with inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Summary of key evidence and regional expert opinion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We address, particularly, the diagnosis of and testing for inhibitors, as well as the epidemiology of inhibitors, including incidence, prevalence and disease burden. Secondly, we provide an overview of the current treatment landscape in HA with inhibitors regarding the eradication of inhibitors with immune tolerance induction and the treatment and prevention of bleeding with bypassing agents, non\u2010factor replacement agents and other experimental therapies. This is complemented with insights from the authors around the applicability of, and challenges associated with, such therapies in their settings of practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We conclude by proposing some key steps towards bridging the gaps in the management of HA with inhibitors in resource\u2010limited countries, including: (1) the collection of quality data that can inform healthcare reforms and policies; (2) improving disease knowledge among healthcare practitioners and patients with the aim of standardising disease management across centres and (3) working towards promoting equal access to HA care and therapies for everyone.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14638","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T20:54:01Z","timestamp":1658523241000},"page":"950-961","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of haemophilia A with inhibitors: A regional cross\u2010talk"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"first","affiliation":[{"name":"Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milanoo  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Kavakli","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology Ege University Children's Hospital  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"El\u2010Beshlawy","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Faculty of Medicine Cairo University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Southampton NHS Foundation Trust  Southampton UK"},{"name":"Clinical Trials and Research Unit KJ Somaiya Super Specialty Hospital and Research Centre  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14010"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01123-X"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61139-2"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S205310"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.01.002"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13747"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208024"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586347"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516437"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-020-00878-5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/15513815.2017.1281363"},{"key":"e_1_2_9_15_1","first-page":"25","article-title":"Inhibitor screening for patients with hemophilia in Turkey","volume":"23","author":"Kavakli K","year":"2006","journal-title":"Turk J Hematol"},{"key":"e_1_2_9_16_1","first-page":"145","article-title":"Factor 8 gene mutation spectrum of 270 patients with hemophilia A: identification of 36 novel mutations","volume":"37","author":"Atik T","year":"2020","journal-title":"Turk J Hematol"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102728"},{"key":"e_1_2_9_18_1","volume-title":"Ulusal Hemofili Tan\u0131 ve Tedavi K\u0131lavuzu Ask\u0131da","author":"T\u00fcrk Hematoloji Derne\u011fi","year":"2021"},{"issue":"1","key":"e_1_2_9_19_1","first-page":"1","article-title":"Inhibitor development upon switch from plasma\u2010derived to recombinant FVIII in PUPs with severe haemophilia A: preliminary analysis of the PUPSWITCH study","volume":"106","author":"Miri S","year":"2021","journal-title":"Haematologica"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-014-0342-z"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13633"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/GJTM.GJTM_35_19"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-01-0049"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00702.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01518.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02611.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1688414"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23957"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2004.00710.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00651.x"},{"key":"e_1_2_9_31_1","first-page":"437","article-title":"Mortality among males with hemophilia: relations with source of medical care","volume":"96","author":"Soucie JM","year":"2000","journal-title":"Blood"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06370.x"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02713.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.7.632"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-1134-3"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01497.x"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00311.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12091"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12730"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04349.x"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03615.x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612943"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01880.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00469.x"},{"key":"e_1_2_9_45_1","first-page":"45","article-title":"The German registry of immune tolerance treatment in hemophilia \u2013 1999 update","volume":"85","author":"Lenk H","year":"2000","journal-title":"Haematologica"},{"issue":"4","key":"e_1_2_9_46_1","first-page":"62","article-title":"Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols","volume":"31","author":"Mariani G","year":"1994","journal-title":"Semin Hematol"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03538.x"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08263.x"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.364"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12608"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1657660"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12730"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.983.983"},{"issue":"10","key":"e_1_2_9_54_1","first-page":"48","article-title":"Immune tolerance induction and the treatment of hemophilia. Malm\u00f6 protocol update","volume":"85","author":"Berntorp E","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01621.x"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-369132"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13064"},{"key":"e_1_2_9_58_1","first-page":"CD010561","article-title":"Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B","author":"Athale AH","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620712464509"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01456-y"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000366"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01218-2"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00934.x"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01379.x"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656122"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4463256.x"},{"issue":"1","key":"e_1_2_9_67_1","first-page":"S61","article-title":"Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high\u2010dose activated factor VII","volume":"9","author":"Hoffman M","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-07-0510"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01772.x"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017988"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00924.x"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02467.x"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104435"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12246"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02663.x"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2015.50.3.173"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02460.x"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02866.x"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12080"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8463"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02329.x"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02693.x"},{"issue":"1","key":"e_1_2_9_83_1","first-page":"9819041","article-title":"Clinical experience with activated factor VII: focus on safety aspects","volume":"9","author":"Roberts HR","year":"1998","journal-title":"Blood Coagul Fibrinol"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00532.x"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-016-0103-3"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1515\/med-2018-0090"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32722-7"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14207"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"issue":"1","key":"e_1_2_9_95_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-134905","article-title":"Real\u2010world safety of emicizumab: the first interim analysis of the European Haemophilia Safety Surveillance (EUHASS) database","volume":"136","author":"Shang A","year":"2020","journal-title":"Blood"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27886"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13877"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13627"},{"key":"e_1_2_9_101_1","unstructured":"Genentech Inc.Highlights of prescribing information. Hemlibra.2017. Accessed October 24 2021.https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14247"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000364"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115495"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908490"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118256"},{"key":"e_1_2_9_108_1","article-title":"Hemostatic response is maintained for up to 5 years following treatment with valoctocogene roxaparvovec, an AAV5\u2010hFVIII\u2010SQ gene therapy for severe hemophilia A [abstract]","volume":"5","author":"Pasi KJ","year":"2021","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14638","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T09:49:27Z","timestamp":1692524967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/hae.14638"],"URL":"https:\/\/doi.org\/10.1111\/hae.14638","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"2022-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}